On 19 March 2009 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending to grant a marketing authorisation for the medicinal product Modigraf, 0.2 mg and 1 mg granules for oral suspension intended for: “Prophylaxis of transplant rejection in adult and paediatric, kidney, liver or heart allograft recipients.
the details can be read here.
No comments:
Post a Comment